General Information of Drug (ID: DMP8QY2)

Drug Name
M1774
Synonyms
674783-97-2; 9-Mesityl-10-methylacridinium Perchlorate; 10-methyl-9-(2,4,6-trimethylphenyl)acridin-10-ium;perchlorate; MFCD09038536; Acridinium, 10-methyl-9-(2,4,6-trimethylphenyl)-, perchlorate; ACMC-209nz7; 9-Mesityl-10-methyl-10-acridinium Perchlorate; [Acr-Mes]+(ClO4)-; SCHEMBL10009695; 10-Methyl-9-(2,4,6-trimethylphenyl)acridinium Perchlorate; DTXSID60580419; ANW-35345; AKOS015843774; SY076797; 9-mesityl-10-methyl-acridinium perchlorate; CS-0103389; 9-Mesityl-10-methylacridin-10-ium perchlorate; 9-Mesityl-10-methylacridinium perchlorate, 95%; 9-Mesityl-10-methylacridinium perchlorate, AldrichCPR; 10-METHYL-9-(2,4,6-TRIMETHYLPHENYL)ACRIDIN-10-IUM PERCHLORATE
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski):
0
Molecular Weight 411.9
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 1
Hydrogen Bond Donor Count 0
Hydrogen Bond Acceptor Count 4
Chemical Identifiers
Formula
C23H22ClNO4
IUPAC Name
10-methyl-9-(2,4,6-trimethylphenyl)acridin-10-ium;perchlorate
Canonical SMILES
CC1=CC(=C(C(=C1)C)C2=C3C=CC=CC3=[N+](C4=CC=CC=C42)C)C.[O-]Cl(=O)(=O)=O
InChI
InChI=1S/C23H22N.ClHO4/c1-15-13-16(2)22(17(3)14-15)23-18-9-5-7-11-20(18)24(4)21-12-8-6-10-19(21)23;2-1(3,4)5/h5-14H,1-4H3;(H,2,3,4,5)/q+1;/p-1
InChIKey
LFMBERYWDLWXNO-UHFFFAOYSA-M
Cross-matching ID
PubChem CID
15953479
CAS Number
674783-97-2
TTD ID
D3OWG9

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Serine/threonine-protein kinase ATR (FRP1) TT8ZYBQ ATR_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04170153) M1774 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors. U.S. National Institutes of Health.
2 National Cancer Institute Drug Dictionary (drug name M1774).